| UHC Commercial Medical & Drug | Denosumab – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Erythropoiesis-Stimulating Agents – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Evkeeza® (Evinacumab-Dgnb) – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Gender Dysphoria Treatment – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Genetic Testing for Cardiac Disease – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Genetic Testing for Hereditary Cancer – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Home Traction Therapy – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Immune Globulin (IVIG and SCIG) – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Leqembi® (Lecanemab-Irmb) – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Lower Extremity Prosthetics – Commercial and Individual Exchange Medical Policy | 2026-04-01 |